drug
discoveri
research
establish
target
impli
number
thing
great
import
result
project
describ
box
box
mani
would
consid
import
advantag
disadvantag
italic
target
valid
tv
discuss
detail
later
systemat
build
evid
interact
propos
target
agent
like
small
molecul
target
id
target
valid
figur
type
drug
discoveri
project
major
stage
involv
progress
poc
anim
advantag
target
id
target
compound
valid
skip
known
compound
assay
avail
tool
higher
averag
probabl
find
efficaci
agent
disadvantag
crowd
market
space
work
need
fast
competit
far
ahead
drug
need
display
clinic
advantag
viabl
market
may
disappear
due
newer
target
mechanist
toxic
formulari
price
regul
may
limit
profit
crowd
ip
space
monoclon
antibodi
mab
therapeut
effect
human
diseas
state
often
far
trivial
see
repres
ongo
laborintens
process
ratelimit
necessari
avoid
disastr
loss
time
money
manpow
occur
clinic
drug
fail
work
target
crucial
diseas
progress
symptom
target
identif
tid
case
process
wherebi
new
target
first
propos
base
minim
evid
less
cumbersom
still
requir
devot
resourc
beauti
work
project
base
upon
alreadi
establish
target
step
skip
exampl
establish
target
would
hmgcoa
reductas
inhibitor
cholesterol
lower
eg
atorvastatin
figur
ppar
agonist
type
ii
diabet
eg
rosiglitazon
figur
compani
go
either
target
today
would
advantag
expens
messi
work
first
identifi
valid
alreadi
done
somebodi
els
dime
like
hundr
million
dollar
new
program
could
therefor
begin
compound
screen
progress
would
nt
deal
annoy
question
peopl
involv
financ
project
often
ask
sure
valid
target
compani
origin
work
preclin
clinic
tv
nt
humanitarian
benevol
confer
good
assay
tool
futur
competitor
instead
definit
alreadi
approv
drug
advanc
clinic
candid
well
way
approv
hope
recoup
cost
project
well
less
success
research
make
shareholderpleas
profit
boot
blockbust
mental
current
less
ensconc
big
pharma
manag
hollywood
one
sure
target
like
draw
whole
flock
compani
particular
water
hole
tri
find
enough
room
squeez
enjoy
may
easi
firstinclass
drug
plethora
compet
drug
probabl
follow
recent
studi
shown
profit
period
market
exclus
singl
firstinclass
approv
drug
exist
given
target
becom
shorter
shorter
averag
year
late
probabl
matter
month
today
studi
use
statist
analysi
drug
approv
date
demonstr
eyeopen
fact
recent
year
secondand
thirdinclass
drug
like
competitor
vy
initi
approv
eventu
firstinclass
winner
copycat
compound
tri
shoehorn
establish
market
later
competitor
nt
happen
win
first
place
race
much
start
target
establish
one
beg
question
exactli
metoo
drug
might
day
dr
albert
wertheim
templ
univers
use
follow
scenario
three
differ
lab
start
within
month
one
success
fda
fewer
question
cro
effici
luckier
get
patient
faster
one
got
fda
approv
first
say
ah
origin
franc
one
came
second
could
first
american
innov
metoo
metoo
like
time
take
brand
new
drug
project
base
establish
target
go
lead
id
approv
drug
probabl
least
year
favor
circumst
target
major
market
phase
ii
clinic
valid
began
alreadi
treat
sever
approv
drug
start
late
rais
new
annoy
incis
question
realli
want
bring
fourthor
fifthinclass
drug
market
research
ever
met
treasur
innov
highli
competit
prospect
seem
excit
enter
race
first
three
winner
announc
gun
even
fire
wo
nt
one
wonder
drug
could
get
signific
market
share
face
competit
research
chemist
particularli
end
work
close
structur
analog
market
drug
frequent
case
kind
project
inevit
think
metoo
project
manag
like
use
eleg
term
like
innov
improv
fast
follow
yet
anoth
tag
sometim
use
type
project
although
mention
fast
appli
geolog
time
scale
certain
element
truth
term
neither
twoword
phrase
explain
realli
go
project
pursu
clinic
establish
target
compani
made
corpor
decis
minim
risk
least
risk
target
failur
respons
signific
fraction
clinic
drug
failur
risk
rel
quit
make
decis
buy
bank
cd
versu
buy
internet
stock
invest
drug
discoveri
busi
truli
low
risk
strategi
everyon
involv
someth
gambler
approach
everyon
confid
least
target
good
one
shown
lead
salabl
therapeut
agent
mani
use
profit
drug
come
approach
approach
per
se
nt
impli
chemist
bore
tear
gener
compound
nearli
ident
known
drug
fall
ip
loophol
patent
poach
anoth
twoword
epitaph
least
theori
establish
target
approach
molecul
resembl
establish
drug
target
compound
look
noth
like
target
nt
necessarili
defin
chemistri
see
sinc
use
known
drug
pharmacophor
start
point
shorten
time
identifi
lead
sometim
type
project
elimin
tid
tv
step
project
base
establish
target
keep
mind
compound
valid
dispens
target
may
good
one
compound
fail
plenti
reason
poor
pk
toxic
etc
although
might
seem
sinc
two
stage
drug
discoveri
process
amput
scheme
fewer
resourc
requir
type
project
need
work
fast
start
behind
mean
nt
alway
full
time
employe
fte
budget
save
elimin
first
two
step
mayb
even
could
requir
get
result
drug
market
still
time
competit
far
aheadassum
one
nt
compet
oneself
second
gener
projectthat
wo
nt
even
remot
possibl
beat
market
compani
hope
sell
drug
physician
prescrib
patient
take
clinic
advantag
need
advantag
exist
drug
give
peopl
reason
use
take
form
greater
efficaci
clinic
studi
prove
work
better
better
dose
regimen
say
daili
oppos
sever
time
day
reduc
toxic
caus
fewer
less
sever
side
effect
thing
mean
medicin
chemist
mean
synthes
select
clinic
candid
emphasi
superior
exist
drug
term
import
hope
measur
properti
vivo
halflif
pk
studi
superior
could
mean
qd
versu
thrice
tid
daili
dose
select
known
antitarget
implic
observ
toxic
exist
drug
advantag
found
best
obtain
someth
equival
alreadi
soon
compani
may
decid
spend
mani
million
dollar
requir
tri
bring
market
catch
often
advantag
disadvantag
may
becom
evid
phase
ii
phase
iii
clinic
trial
even
later
realli
say
short
candid
obviou
advantag
might
still
move
forward
project
drug
becom
much
harder
sell
intern
extern
new
drug
good
old
one
best
pharmaceut
detail
sale
rep
busi
abl
significantli
move
product
regardless
mani
free
sampl
give
away
exist
drug
caus
particular
signific
toxic
patient
nt
stand
good
chanc
take
away
larg
amount
market
share
exist
drug
like
oral
anticoagul
warfarin
difficult
dose
correctli
due
narrow
therapeut
window
lot
individu
variabl
new
vitamin
k
reductas
inhibitor
reason
nt
thing
equal
drug
like
take
market
coupl
myth
exist
mind
mani
research
need
explod
first
firstinclass
mean
bestinclass
least
asgoodasanyotherinclass
way
come
new
drug
nt
terribl
differ
come
new
product
say
new
car
henri
ford
model
outperform
car
driveway
ford
still
sell
lot
new
drug
busi
evolutionari
process
term
target
given
diseas
drug
treat
one
target
mean
firstinclass
eventu
even
becom
worstinclass
prescript
drug
like
anyth
els
imperfect
plenti
room
improv
exampl
provid
hope
labor
come
new
drug
establish
target
lipitor
atorvastatin
figur
current
prescript
drug
sold
anywher
billion
annual
worldwid
sale
fifth
statin
approv
fda
make
market
nine
year
firstinclass
compound
mevacor
lovastatin
figur
least
one
major
studi
demonstr
improv
effect
ldllower
atorvastatin
rel
statin
low
incid
nasti
fortun
rare
side
effect
compound
class
rhabdomyolysi
factor
includ
market
might
pfizer
doubt
big
part
lipitor
success
stori
point
work
yet
anoth
drug
establish
target
sometim
legitim
formula
success
point
view
corpor
execut
patient
take
even
excit
project
chemist
consid
structur
lovastatin
atorvastatin
shown
figur
lactonecontain
side
chain
former
upon
hydrolysi
gener
import
pharmacophor
contain
side
chain
latter
well
drug
class
see
appendix
period
tabl
drug
realli
much
similar
lovastatin
look
like
fungal
metabolit
atorvastatin
nt
look
like
natur
product
nt
instead
result
determin
synthet
effort
group
chemist
warnerlambert
work
interest
commerci
scale
enantioselect
synthesi
inde
innov
improv
one
doubt
chemist
involv
found
project
trivial
bore
differ
molecular
structur
drug
key
second
myth
need
explod
find
new
drug
given
target
structur
quit
differ
known
drug
target
provid
sort
advantag
drug
synthet
chemist
never
fond
true
metoo
patent
poach
project
aim
find
hole
exist
patent
via
someth
like
one
atom
replac
desper
corpor
execut
transfix
gantt
chart
could
love
project
chemist
would
rather
make
novelmean
highli
dissimilarstructur
dissimilar
structur
per
se
convey
advantag
clinic
physician
go
ask
patient
would
nt
rather
take
oxazol
pyrimidin
drug
reach
clinic
test
structur
larg
irrelev
two
thing
realli
matter
safeti
efficaci
compound
need
demonstr
uniqu
oxazol
less
like
pyrimidin
biotransform
toxic
metabolit
allow
question
becom
would
nt
rather
take
safer
compound
danger
one
clinic
market
advantag
obviou
structur
dissimilar
probabl
provid
basi
new
chemistri
new
paper
patent
realli
benefit
unless
result
drug
greater
efficaci
andor
less
toxic
known
drug
target
fall
flat
anoth
potenti
disadvantag
use
establish
target
strategi
market
drug
act
given
target
suddenli
disappear
anoth
better
target
come
along
older
cholesterol
lower
drug
introduct
statin
begin
mevacor
one
look
market
condit
assess
year
ago
project
market
given
diseas
go
anoth
year
road
drug
market
today
earli
crystal
ball
hard
come
busi
might
end
new
improv
edsel
signific
improv
nobodi
buy
danger
rare
toxic
bane
pharmaceut
industri
day
might
also
encount
recal
mention
sever
time
real
clinic
advantag
requir
strategi
work
clinic
advantag
ca
nt
alway
predict
advanc
neither
idiosyncrat
toxic
toxic
seen
known
drug
act
given
target
nt
go
immedi
clear
whether
said
toxic
compound
toxic
mechanist
toxic
latter
would
doom
drug
act
target
former
might
instead
provid
better
opportun
compet
drug
class
grab
market
share
appar
exampl
compounddepend
toxic
seen
metformin
phenformin
stori
glucophag
metformin
figur
biguanidin
thought
act
via
multipl
yet
fulli
elucid
mechan
exert
blood
glucos
lower
effect
anoth
structur
similar
drug
phenformin
figur
thought
util
sort
mechan
year
use
diabet
patient
shown
associ
unaccept
highrisk
lifethreaten
lactic
acidosi
fortun
metformin
nt
share
case
although
theoret
basi
mechanist
toxic
might
postul
buildup
lactic
acid
due
hepat
gluconeogenesi
inhibit
one
effect
drug
appear
toxic
larg
compound
depend
phenformin
withdrawn
us
market
metformin
still
brisk
sale
two
diabet
drug
ppar
agonist
rezulin
troglitazon
withdrawn
market
due
liver
toxic
avandia
rosiglitazon
still
import
drug
today
although
one
recent
highlight
anoth
toxic
concern
share
similar
stori
differ
type
toxic
involv
situat
occur
one
might
even
wonder
fast
follow
metoo
approach
could
count
type
possibl
scenario
potenti
advantag
would
like
set
shop
next
door
competitor
fervent
hope
lightn
strike
elimin
busi
wors
would
ridicul
strategi
risk
market
drug
act
establish
target
might
disappear
either
better
target
found
unexpect
mechanist
toxic
discov
one
add
risk
futur
fewer
drug
compet
given
indic
could
due
increasingli
restrict
formulari
look
cover
prescript
cheapest
drug
class
could
due
increas
pressur
us
govern
regul
drug
price
happen
seen
chapter
believ
would
hard
pharma
compani
justifi
highiniti
price
fourthinclass
fifthinclass
drug
regardless
advantag
reason
mani
peopl
believ
back
mani
drug
base
establish
target
good
idea
risk
level
approach
nt
low
object
built
futur
scenario
may
may
come
pass
anoth
difficulti
approach
seen
everi
day
new
drug
discoveri
busi
plain
hard
find
ip
space
drug
act
establish
target
often
alreadi
hundr
exist
compositionofmatt
patent
issu
compound
act
target
markush
structur
impli
compound
star
heaven
gaze
page
page
descript
structur
bring
chemist
closer
true
understand
infin
mention
despair
ever
find
someth
cover
add
fear
even
happen
upon
someth
claim
exist
patent
nt
mean
work
nt
alreadi
underway
somewher
cover
futur
one
saw
chapter
take
month
date
file
patent
applic
publish
whatev
hole
find
publish
one
may
process
patch
ever
find
even
lead
may
come
screen
appear
proprietari
may
mean
might
imposs
find
patent
compound
develop
come
establish
therapeut
target
patent
gener
mean
project
studi
industri
consist
show
project
base
establish
target
like
reach
clinic
stage
like
succeed
clinic
project
base
nonestablish
target
short
seen
winner
keep
mind
although
disadvantag
may
outnumb
advantag
shown
box
singl
advantag
higher
averag
probabl
find
efficaci
agent
often
thought
outweigh
neg
result
larg
percentag
new
drug
project
fall
categori
research
chemist
expect
get
plenti
experi
work
second
type
establish
target
project
exist
number
disadvantag
obviat
dr
han
maag
vice
presid
chemistri
roch
palo
alto
refer
tough
target
nt
know
actual
start
chemistri
biolog
pretti
clear
cut
biologicsantibodi
onout
commerci
success
want
make
small
molecul
basic
target
alreadi
valid
question
matter
valid
target
want
find
small
molecul
interfer
target
either
alloster
otherwis
explain
exampl
kind
target
tumor
necrosi
factor
tnf
import
cytokin
shown
key
player
mani
inflammatori
disord
includ
rheumatoid
arthriti
pain
debilit
difficulttotreat
diseas
antitnfa
antibodi
remicad
infliximab
humira
adalimumab
enbrel
etanercept
solubl
form
ligand
bind
region
tnfa
receptor
proven
beyond
doubt
valid
tnfa
target
biolog
requir
inject
carri
risk
immunogen
mention
highpric
tag
small
molecul
interf
bind
tnfa
receptor
would
nt
carri
liabil
would
like
becom
billion
dollar
drug
although
small
molecul
known
interact
somewher
along
tnfa
pathway
like
thalomid
thalidomid
somehow
reduc
tnfa
level
thu
least
sort
pathway
valid
molecul
could
directli
interfer
bind
tnfa
receptor
therebi
mimick
effect
remicad
humira
proven
hard
come
project
direct
encount
usual
difficulti
tri
mimic
proteinprotein
interact
small
molecul
although
recent
public
sunesi
describ
small
molecul
inhibitor
interact
act
essenti
displac
one
subunit
normal
trimer
ligand
project
direct
small
molecul
interact
target
alreadi
valid
marketplac
biolog
drug
advantag
obviou
ip
space
wide
open
sinc
probabl
one
els
agent
either
although
may
look
one
market
result
drug
almost
guarante
stumbl
block
must
underestim
find
agentit
clear
done
save
grace
failur
identifi
good
lead
would
least
happen
earli
project
synthet
scheme
trickiest
step
one
first
one
last
step
invest
much
time
energi
hope
oftrep
aphor
drug
discoveri
go
fail
fail
earli
look
two
flavor
project
base
upon
establish
target
one
nearer
dearer
chemist
heart
vanguard
biotech
pharmaceut
research
new
target
although
human
genom
contain
slightli
gene
due
posttransl
modif
altern
splice
protein
complex
associ
might
make
excess
one
million
differ
protein
mention
nonprotein
target
human
targetom
small
percentag
expect
provid
good
therapeut
target
seen
chapter
genom
till
date
proven
far
capabl
elucid
rare
inherit
disord
stem
mutat
singl
protein
identifi
new
target
common
diseas
expect
flood
new
target
nt
materi
day
new
tid
larg
shift
scienc
proteom
differenti
express
given
protein
diseas
versu
normal
cell
tissu
often
start
point
investig
whether
constitut
good
target
drug
potenti
target
stem
sourc
progress
understand
biochem
pathway
ratelimit
step
new
target
identifi
phenotyp
screen
describ
later
differenti
protein
express
probabl
common
sourc
propos
new
target
exampl
would
includ
overexpress
given
protein
number
differ
tumor
cell
line
correl
aggress
highli
metastat
tumor
probabl
thousand
protein
examin
industri
academia
alreadi
sinc
data
rais
possibl
might
crucial
tumorigenesi
tumor
growth
tumor
spread
case
number
caveat
need
kept
mind
first
express
data
obtain
use
microarray
reflect
mrna
level
nt
necessarili
correl
protein
concentr
turn
nt
necessarili
correl
protein
activ
level
concentr
two
protein
rel
mrna
level
might
differ
show
transcript
level
provid
littl
predict
valu
respect
extent
protein
express
protein
produc
activ
form
requir
process
associ
protein
modul
say
endogen
inhibitor
whose
level
might
vari
interpret
data
scientist
keep
mind
mani
slip
twixt
cup
lip
second
dynam
natur
protein
express
mean
alway
celland
timedepend
express
level
earli
stage
tumor
cell
probabl
vari
consider
later
stage
tumor
may
littl
common
protein
express
level
say
endotheli
cell
line
tumor
vasculatur
tumor
cell
aerob
environ
near
blood
vessel
differ
proteom
profil
one
buri
deep
insid
tumor
anaerob
environ
kind
issu
complic
interpret
protein
express
type
tissu
importantli
correl
ca
nt
establish
causat
omic
technolog
give
us
correl
data
realli
need
caus
data
say
dr
david
szymkowski
director
biotherapeut
xencor
monrovia
california
point
reason
behind
assumpt
protein
overexpress
given
diseas
state
valid
therapeut
target
analog
follow
bit
il
logic
firemen
found
burn
hous
firemen
found
normal
hous
therefor
firemen
caus
hous
fire
therefor
elimin
firemen
prevent
fire
overexpress
protein
diseas
state
might
actual
defens
respons
someth
one
want
elimin
second
possibl
especi
worth
consid
wed
occur
june
month
suicid
occur
june
month
therefor
wed
caus
suicid
therefor
elimin
wed
prevent
suicid
increas
decreas
protein
express
given
diseas
state
entir
coincident
protein
question
like
innoc
bystand
caus
agent
vast
major
protein
differenti
express
given
diseas
fall
two
categori
clearli
launch
new
project
base
target
howev
excit
subsequ
commit
money
manpow
justifi
equal
commit
find
firmer
evid
soon
possibl
drop
project
quickli
evid
forthcom
everyth
depend
tv
term
target
valid
mean
differ
thing
differ
peopl
chemist
propos
new
project
might
refer
affirm
evid
mous
knockout
even
rna
interfer
rnai
experi
cell
clinician
probabl
mean
less
proven
statist
signific
efficaci
drug
larg
scale
control
human
trial
strictest
sens
clinician
right
real
world
obvious
imposs
put
agent
act
everi
new
propos
target
clinic
find
whether
valid
sinc
howev
need
new
drug
act
new
target
real
seri
mileston
demonstr
target
import
cell
anim
need
met
time
target
identifi
time
drug
act
enter
clinic
closer
compound
get
clinic
farther
along
project
advanc
higher
bar
becom
mention
earlier
mean
tv
nt
consist
singl
experi
instead
ongo
process
best
thought
target
confid
build
closer
project
get
clinic
expens
becom
confid
inde
target
valid
one
requir
satisfi
scientist
manag
investor
number
author
comment
need
stage
tv
suggest
mileston
might
use
defin
stage
tabl
show
one
possibl
system
might
use
worth
good
look
level
none
includ
remind
initi
identifi
target
way
assum
valid
one
use
cancer
analog
level
valid
might
consist
evid
show
block
function
protein
x
induc
apoptosi
variou
cancer
cell
line
less
effect
normal
cell
tool
thu
perturb
protein
function
rnai
knockout
antibodi
etc
vari
discuss
next
section
differ
result
sometim
obtain
differ
tool
earli
stage
project
usual
lack
small
molecul
capabl
select
interf
singl
desir
target
point
tv
experi
often
use
method
ultim
small
molecul
provid
best
valid
small
molecul
drug
goal
mani
propos
target
drop
even
lowest
valid
level
nt
push
onto
develop
tool
small
molecul
antibodi
etc
capabl
select
perturb
target
anim
model
diseas
achiev
first
vivo
proofofconcept
poc
thu
reach
level
ii
valid
scheme
major
mileston
caus
celebr
project
still
nt
prove
efficaci
drug
around
corner
level
ii
valid
cancer
might
mean
tumor
growth
inhibit
better
still
regress
xenograft
use
human
cancer
cell
immun
compromis
anim
syngen
use
cancer
nativ
speci
mous
model
cancer
especi
efficaci
singl
model
nt
realli
predict
human
clinic
success
gener
true
compound
work
mani
differ
model
better
shot
clinic
efficaci
one
effect
upshot
mani
indic
level
ii
valid
need
establish
multipl
model
mean
much
program
produc
clinic
candid
new
target
true
test
valid
approach
failur
achiev
viabl
safeti
profil
pharmacokinet
properti
withdraw
due
busi
reason
sometim
mean
new
target
end
neither
valid
invalid
proof
efficaci
phase
ii
studi
though
first
studi
realli
design
look
first
level
valid
man
level
iii
achiev
even
valid
unequivoc
disappoint
case
clinic
efficaci
ca
nt
reproduc
second
phase
ii
studi
later
phase
iii
trial
henc
highest
level
target
confid
level
iv
valid
reserv
drug
target
run
full
gamut
success
reach
mileston
valid
new
target
probabl
biggest
challeng
met
drug
discoveri
difficulti
major
factor
rel
dearth
drug
aim
new
target
get
approv
year
drug
discoveri
project
direct
novel
target
need
target
confid
build
get
along
way
fortun
wide
varieti
valid
tool
nowaday
avail
discuss
next
section
abil
produc
anim
lack
particular
gene
product
interest
allow
research
look
diseaserelev
phenotyp
becom
power
tool
valid
target
figur
genet
similar
human
mice
gener
use
although
much
inform
also
gain
knockout
experi
lower
organ
like
caenorhabd
elegan
drosophila
three
type
anim
compar
wild
type
heterozygot
homozygot
crude
sort
dosedepend
sometim
note
phenotyp
knockout
mice
proven
use
valid
mani
drug
target
one
good
exampl
cystein
proteas
cathepsin
k
enzym
mostli
found
osteoclast
special
type
cell
involv
bone
remodel
cathepsin
k
proteolyt
enzym
whose
purpos
thought
degrad
collagen
matrix
left
decalcif
process
bone
resorpt
osteoporosi
diseas
character
low
bone
densiti
one
particularli
preval
problemat
age
popul
believ
repres
imbal
bone
buildup
bone
breakdown
cathepsin
k
play
import
role
latter
inhibit
function
might
provid
effect
way
treat
diseas
cathepsin
k
mice
gener
found
abnorm
dens
bone
sever
impair
bone
resorpt
provid
measur
valid
target
osteoporosi
valid
along
sever
clinic
candid
aim
sinc
appear
studi
research
lexicon
genom
lexicon
pharmaceut
look
target
top
prescript
drug
found
target
knockout
model
could
gener
case
knockout
produc
phenotyp
inform
therapeut
indic
involv
lexicon
also
nation
institut
health
nih
embark
project
aim
knock
gene
found
mous
like
tool
though
knockout
nt
univers
applic
free
problem
although
mani
knockout
mice
commerci
avail
expens
requir
quit
bit
time
money
gener
mani
case
say
time
other
say
frequent
knockout
result
embryon
neonat
lethal
absent
protein
appar
requir
proper
develop
whether
need
later
happen
cours
inform
target
protein
role
matur
anim
ca
nt
obtain
although
sometim
lethal
mean
someth
find
embryon
lethal
due
defect
blood
vessel
format
heterozyg
vascular
endotheli
growth
factor
vegf
knockout
impli
natur
nt
good
way
compens
loss
angiogenesi
provid
key
piec
inform
develop
antiangiogen
anticanc
compound
like
avastin
vegf
antibodi
gener
natur
adept
compens
loss
incred
varieti
protein
present
problem
phenotyp
one
expect
observ
nt
compens
redund
mechan
happen
develop
surprisingli
differ
phenotyp
sometim
observ
knockout
differ
strain
mice
use
furthermor
phenotyp
observ
knockout
mice
import
ppar
receptor
heterozyg
knockout
mice
demonstr
improv
sensit
insulin
fed
highfat
diet
suggest
strategi
use
ppar
antagonist
treat
diabet
howev
antidiabet
thiazolidinedion
like
rosiglitazon
improv
insulin
sensit
ppar
agonist
needless
say
took
bit
explain
one
big
reason
knockout
result
may
correspond
result
obtain
use
small
molecul
prospect
target
protein
may
well
involv
one
particular
activ
small
molecul
might
target
small
molecul
might
interfer
bind
ligand
one
site
protein
often
multidomain
form
necessari
complex
protein
via
interact
affect
small
molecul
effect
illustr
graphic
figur
mean
small
molecul
capabl
tweak
protein
knockout
name
impli
nt
exactli
light
tap
cheek
knockout
gene
result
complet
loss
target
protein
disrupt
protein
complex
impair
function
domain
would
unaffect
drug
secondari
effect
domin
phenotyp
knockout
knockout
small
molecul
inhibitor
target
protein
produc
differ
outcom
author
quot
recommend
less
bluntforc
transgen
method
replac
target
protein
mutant
lack
catalyt
activ
knockin
rather
delet
altogeth
predict
altern
knockout
provid
exampl
kinas
two
techniqu
produc
opposit
phenotyp
along
techniqu
like
condit
knockout
absenc
protein
induc
specif
desir
tissu
knockin
provid
addit
use
tool
tv
research
harvard
report
deoxynucleotid
segment
complementari
section
rou
sarcoma
viru
mrna
could
block
viru
product
cell
cultur
later
work
demonstr
antisens
oligonucleotid
ao
vari
length
bind
target
mrna
sequenc
watsoncrick
base
pair
either
lead
cleavag
mrna
enzym
rnase
h
prevent
translat
mechan
end
result
howev
product
target
protein
shut
see
figur
nake
oligo
like
use
rou
sarcoma
viru
rare
use
nowaday
normal
nt
stabl
presenc
nucleas
endogen
enzym
cleav
minut
mean
chemic
modif
normal
requir
stick
around
long
enough
good
effect
one
earliest
consist
use
modif
involv
replac
nonbridg
oxygen
atom
phosphat
linkag
sulfur
atom
result
phosphorothio
deoxyoligonucleotid
other
involv
alkyl
hydroxi
group
ribonucleotid
oligom
methyl
methoxyethyl
group
also
seem
increas
affin
target
mrna
gener
methylphosphon
place
phosphat
linkag
variou
modif
base
ribos
moieti
even
go
far
replac
ribos
ring
morpholin
polyamid
sometim
chimer
oligo
incorpor
sever
modif
differ
posit
use
everi
stretch
given
protein
mrna
sequenc
good
site
ao
bind
experiment
requir
sinc
gene
sequenc
inform
secondari
tertiari
protein
structur
inform
requir
design
tool
compound
gener
much
quickli
small
molecul
inhibitor
get
cell
howev
nt
alway
straightforward
work
better
type
cell
other
method
transfect
includ
use
polycation
reagent
liposom
special
techniqu
like
electropor
microinject
antisens
oligonucleotid
proven
use
tv
cell
anim
embryon
lethal
often
seen
knockout
issu
limit
though
includ
possibl
nonspecif
effect
due
interact
variou
protein
toxic
due
transfect
reagent
need
use
use
knockout
tv
absenc
presenc
inact
form
target
protein
might
invok
phenotyp
differ
seen
small
molecul
inhibitor
unlik
knockout
howev
target
protein
probabl
absent
use
antisens
techniqu
although
knockdown
often
achiev
importantli
sinc
antisens
reagent
interact
cell
anim
alreadi
target
protein
present
mere
prevent
futur
product
lot
depend
halflif
exist
protein
order
day
happen
may
take
least
long
antisens
knockdown
effect
phenotyp
yet
anoth
reason
ao
need
stabl
case
everi
tv
tool
mention
section
except
knockout
ao
human
therapeut
potenti
well
vitraven
fomivirsen
phosphorothio
pioneer
antisens
compani
isi
pharmaceut
approv
use
cmv
retin
patient
hiv
drug
inject
intravitr
eye
anoth
isi
antisens
drug
isi
target
shown
promis
phase
ii
clinic
trial
cholesterol
lower
effect
compar
obtain
atorvastatin
drug
given
subcutan
sc
inject
antisens
drug
clinic
trial
well
antisens
oligonucleotid
remain
import
valid
therapeut
mani
way
recent
eclips
popular
anoth
techniqu
direct
mrna
call
rnai
twenti
year
discoveri
ao
could
block
translat
mrna
target
protein
anoth
method
posttranscript
target
knockdown
found
dr
andrew
fire
carnegi
institut
washington
dr
craig
mello
univers
massachusett
cowork
publish
paper
demonstr
inject
low
level
doubl
strand
rna
dsrna
c
elegan
could
inhibit
express
target
protein
sequenc
specif
manner
mechan
differ
observ
ao
subsequ
work
uncov
detail
new
type
rna
interfer
rnai
eventu
led
award
nobel
prize
medicin
figur
outlin
current
understand
process
involv
long
dsrna
like
one
use
report
cleav
nucleas
dicer
produc
doubl
strand
sever
unpair
nucleotid
overhang
end
also
phosphat
group
call
small
interf
rna
sirna
unwind
strand
associ
rnainduc
silenc
complex
risc
allow
antisens
strand
guid
complex
target
mrna
hybrid
right
mrna
sens
sequenc
bound
mrna
cleav
center
cognat
sequenc
catalyt
mechan
believ
evolv
defens
virus
simpl
organ
lack
complex
immun
system
nt
use
way
mammal
put
ds
rna
segment
longer
nucleotid
mammalian
cell
problemat
interferon
respons
induc
cell
tend
die
rnai
normal
achiev
use
presynthes
nucleotid
sirna
reagent
transfect
cell
use
method
carrier
electropor
similar
use
ao
figur
b
introduc
dna
vector
short
hairpin
rna
shrna
convert
relev
sirna
reagent
within
cell
nake
sirna
doubl
strand
stabl
nake
ao
unlik
latter
normal
fine
cellular
experi
vivo
use
ad
exogen
stabil
pk
paramet
perhap
affin
might
need
improv
sort
chemic
modif
phosphorothio
etc
use
antisens
reagent
reagent
sirna
experi
cell
probabl
easiest
tv
tool
come
design
sole
basi
gene
sequenc
order
internet
vast
sirna
librari
purchas
well
ao
get
compound
cell
trickiest
part
whole
process
multipl
control
contain
mismatch
need
use
actual
target
protein
level
need
determin
conclus
arriv
compar
effort
involv
find
potent
select
small
molecul
inhibitor
target
rnai
constitut
much
easier
rout
earli
tv
particularli
class
target
good
small
molecul
tool
hard
come
studi
compar
use
sirna
ao
found
former
effect
lower
concentr
advantag
go
long
way
toward
explain
increas
popular
rnai
tv
typic
recent
exampl
commerci
avail
sirna
target
matrix
imped
cell
prolifer
result
apoptosi
mous
hepatocarcinoma
cell
line
hcaf
attenu
metastat
potenti
cell
mous
model
research
genentech
took
advantag
condit
rnai
newer
techniqu
show
knock
braf
serinethreonin
kinas
slow
tumor
growth
one
xenograft
mous
model
metastat
melanoma
caus
regress
anoth
thu
provid
vivo
valid
braf
cancer
target
small
molecul
inhibitor
novel
target
exist
select
origin
rnai
thought
exquisit
specif
desir
target
recent
call
question
offtarget
effect
report
mismatch
reagent
target
mrna
may
thu
toler
one
possibl
sirna
might
case
act
like
cousin
microrna
import
newli
discov
regul
mammalian
protein
translat
seem
act
nonspecif
recogn
seven
nucleotid
anoth
possibl
sens
strand
sirna
duplex
normal
assum
degrad
still
play
role
sometim
nonspecif
effect
sirna
area
ongo
research
thing
need
kept
perspect
offtarget
activ
sirna
receiv
larg
press
coverag
late
difficulti
obtain
smallmolecul
specif
ongo
struggl
within
pharmaceut
industri
mani
year
would
make
argument
use
sirna
reagent
chemist
alleg
lack
specif
littl
like
pot
call
kettl
black
specif
issu
tv
tool
matter
therapeut
modal
method
demonstr
specif
especi
use
rescu
experi
ad
back
gene
product
via
transcript
sequenc
sirna
nt
target
use
multipl
sirna
reagent
target
differ
part
transcript
suggest
anoth
assumpt
dsrna
less
nucleotid
read
sirna
never
caus
interferon
respons
also
call
question
kind
problem
expect
young
technolog
mani
way
remark
thing
far
come
short
time
rnai
therapeut
alreadi
undergo
clinic
trial
one
compani
involv
technolog
sirna
therapeut
recent
acquir
merck
billion
indic
promis
industri
feel
technolog
ultim
rnai
certainli
deserv
seat
tv
tabl
main
advantag
small
molecul
eas
reagent
design
construct
method
perfect
cours
suggest
much
util
rnai
tv
tool
lie
combin
screen
tool
exampl
recent
use
genomewid
sirna
screen
identifi
gene
sensit
nonsmal
cell
lung
cancer
nsclc
cell
effect
paclitaxel
experi
could
help
point
way
new
therapeut
target
well
ration
combin
therapi
cancer
antibodi
repres
endogen
method
target
extracellular
protein
dozen
monoclon
antibodi
mab
deriv
one
clone
recogn
one
antigen
approv
therapeut
use
mostli
cancer
inflammatori
diseas
liter
hundr
clinic
account
massiv
amount
research
go
area
also
use
exquisit
select
tv
tool
provid
target
extracellular
one
figur
show
structur
full
length
antibodi
high
molecular
weight
kda
partli
explain
normal
ca
nt
use
intracellular
target
highli
cell
imperm
even
introduc
full
length
mab
cell
microinject
express
cell
problemat
reduc
environ
insid
cell
nt
allow
disulfid
bond
necessari
antibodi
maintain
right
conform
antibodi
produc
intracellularli
nt
fold
properli
extracellular
target
although
nt
quit
simpl
make
sirna
antibodi
proven
use
earli
stage
drug
discoveri
via
librari
gener
phage
display
tool
studi
physiolog
role
extracellular
protein
like
selectin
one
nice
thing
use
tv
target
prove
valid
use
mab
use
establish
might
develop
therapeut
agent
gener
mab
bind
select
desir
effect
function
given
challeng
recent
year
seen
grow
interest
intrabodi
intracellular
antibodi
shown
figur
c
usual
consist
light
chain
v
l
heavi
chain
v
h
antibodi
domain
contain
bind
recognit
element
held
togeth
peptid
linker
refer
singl
chain
fv
fragment
scfv
genet
engin
normal
use
express
cell
effect
sometim
depend
abil
redirect
target
protein
differ
locat
within
cell
via
peptid
sequenc
attach
function
cellular
zip
code
observ
biggest
barrier
effect
scfv
often
stabil
solubl
bind
affin
per
se
despit
limit
intrabodi
proven
use
valid
experi
cystein
proteas
cathepsin
l
cancer
hepat
c
serin
proteas
liver
cancer
among
other
size
molecul
intrabodi
antibodi
excit
abil
affect
proteinprotein
interact
small
molecul
usual
good
mode
action
limit
time
lag
involv
slow
protein
turnov
take
effect
soon
reagent
besid
use
ao
sirna
reagent
oligonucleotid
find
yet
anoth
use
perturbogen
tv
studi
aptam
term
refer
short
nucleotid
stretch
dna
rna
fold
way
confer
shape
complementar
target
protein
peptid
aptam
exist
well
common
antibodi
fragment
like
discuss
oligonucleotid
aptam
select
pool
candid
autom
vitro
process
call
systemat
evolut
ligand
exponenti
enrich
selex
complet
day
protein
also
small
molecul
metal
ion
target
rna
aptam
found
bind
theophyllin
greater
affin
methyl
analog
caffein
aptam
nt
seem
induc
immunogen
given
vivo
often
major
limit
antibodi
one
recent
exampl
use
aptam
studi
potenti
target
make
use
rna
spiegelm
spiegel
german
mirror
mirror
imag
oligonucleotid
made
lribos
sugar
place
normal
dribos
ring
result
compound
resist
degrad
nucleas
day
aptam
call
bind
octanoylghrelin
nanomolar
potenc
ghrelin
acid
peptid
endogen
ligand
growth
hormon
secretagogu
receptor
potenti
obes
target
get
lot
press
coverag
pegyl
found
inhibit
ghrelin
effect
central
nervou
system
cn
vivo
experi
successor
spiegelm
produc
weight
loss
dietinduc
mous
obes
model
aptam
find
use
extracellular
target
antibodi
intracellular
version
technolog
also
exist
case
call
intram
good
review
use
aptam
tv
recent
publish
emphas
util
aptam
ht
assay
well
aptam
drug
vegf
antagonist
macugen
recent
approv
fda
treatment
agerel
macular
degener
amd
like
antivir
ao
drug
vitraven
macugen
inject
eye
sever
aptam
clinic
well
read
preced
section
reader
probabl
wo
nt
need
much
convinc
small
molecul
usual
make
best
tool
use
valid
target
perhap
best
way
consid
advantag
small
molecul
bring
look
disadvantag
lack
embryon
lethal
compens
develop
structur
effect
due
absenc
normal
proteinprotein
interact
long
delay
administr
effect
difficulti
determin
doserespons
immunogen
interferon
respons
extrem
challeng
intracellular
deliveri
gener
unsuit
oral
administr
without
problem
find
select
small
molecul
inhibitor
scratch
probabl
difficult
find
function
sirna
tool
chemist
ca
nt
look
sequenc
gene
design
small
molecul
inhibitor
order
onlin
problem
select
cell
permeabl
oral
bioavail
stranger
medicin
chemist
keep
mind
drug
market
continu
small
molecul
ultim
project
direct
compound
need
use
valid
experi
includ
clinic
studi
although
valid
tool
help
along
way
particularli
use
combin
project
small
molecul
real
thing
purpos
book
line
establish
target
novel
one
drawn
clinic
efficaci
phase
ii
repres
level
iii
tv
accord
scheme
describ
earlier
definit
target
novelti
therefor
encompass
everyth
target
complet
lack
valid
target
proven
work
multipl
anim
model
given
diseas
see
repres
wide
vari
degre
novelti
includ
target
exist
mind
singl
scientist
target
posit
anim
model
data
alreadi
publish
scienc
natur
project
differ
base
establish
target
box
summar
advantag
disadvantag
project
direct
novel
target
first
work
project
direct
novel
target
research
scientist
gener
go
excit
therefor
motiv
factor
underestim
prospect
design
make
one
hand
firstinclass
section
novel
target
drug
especi
structur
novel
one
fill
unmet
need
probabl
translat
greater
effort
creativ
focu
even
jade
veteran
medicin
chemist
nt
dreamt
come
next
gleevec
imatinib
breakthrough
bcrabl
kinas
inhibitor
dramat
improv
extend
live
patient
chronic
myeloid
leukemia
cml
contribut
firstinclass
inhibitor
cancer
cathepsin
k
inhibitor
osteoporosi
appeal
scientist
come
fourthinclass
drug
everyon
know
differ
motiv
employe
lackadais
one
nightandday
one
might
think
first
new
target
would
bring
wide
open
ip
space
novel
target
per
se
impli
novel
compound
lot
depend
differ
target
known
one
see
later
lead
new
target
member
known
famili
kinas
aspartyl
proteas
often
found
librari
compound
activ
protein
famili
member
situat
screen
aminoquinazolin
librari
turn
hit
new
kinas
target
class
compound
extens
claim
kinas
inhibitor
patent
literatur
although
target
may
new
inhibitor
probabl
old
may
much
ip
room
novel
target
significantli
differ
popular
wellexplor
target
better
chanc
structur
novel
lead
bind
identifi
one
found
although
target
nt
dictat
compound
certain
amount
influenc
novel
target
although
patent
lebensraum
nt
necessarili
come
territori
market
space
even
crowd
therapeut
area
mani
effect
drug
exist
drug
interven
differ
point
alway
welcom
firstinclass
renin
inhibitor
aliskiren
figur
recent
approv
treatment
hypertens
good
exampl
renin
aspartyl
proteas
involv
earli
angiotensin
pathway
well
known
angiotensin
convert
enzym
ace
involv
later
larg
regul
blood
pressur
renin
inhibitor
around
decad
inhibitor
tend
rather
larg
peptidelik
compound
problem
oral
bioavail
advantag
motiv
project
scientist
market
space
potenti
market
exclus
potenti
advantag
synergi
drug
disadvantag
requir
valid
may
benchmark
compound
relev
assay
high
attrit
rate
kept
becom
drug
appear
aliskiren
renin
inhibitor
project
notabl
eventu
provid
lead
anoth
aspartyl
proteas
came
along
much
later
hiv
proteas
surprisingli
oral
bioavail
alway
seem
major
obstacl
develop
class
drug
great
effort
decad
work
obstacl
overcom
three
point
appar
stori
first
target
given
famili
tend
prefer
structur
relat
compound
second
even
difficult
problem
eventu
overcom
given
suffici
incent
third
origin
point
market
space
exist
drug
novel
mechan
action
moa
aliskiren
made
market
singl
agent
combin
use
antihypertens
expect
provid
winwin
situat
maker
novarti
need
new
drug
albeit
one
differ
target
mani
avail
alreadi
two
reason
encount
better
efficaci
andor
better
safeti
either
new
agent
alon
combin
therapi
exist
drug
one
could
easili
ask
organ
chemist
need
one
way
put
silyl
protect
group
sometim
favorit
way
either
nt
work
work
well
silyl
thing
answer
break
reactiv
select
curious
similar
drug
crucial
attribut
efficaci
safeti
chemist
intuit
realiz
transform
dozen
reagent
condit
exist
popular
andor
difficult
one
analog
situat
appli
drug
use
drug
act
new
target
combin
anoth
exist
drug
particularli
attract
proposit
especi
come
difficult
lifethreaten
diseas
therapeut
need
help
get
like
hepat
c
viru
hcv
hiv
cancer
hope
remain
someday
singl
agent
efficaci
enough
least
keep
diseas
check
even
cure
may
avail
realiti
drug
exist
today
exist
therapeut
work
limit
differ
class
avail
frequent
use
togeth
kind
combin
therapi
discuss
chapter
benefici
effect
addit
better
yet
synergist
although
studi
need
carri
make
sure
toxic
nt
synergist
approach
best
exemplifi
hiv
drug
first
target
broach
war
fearsom
viru
enzym
call
revers
transcriptas
rt
viru
requir
convert
genom
rna
dna
first
approv
drug
target
nucleosid
analog
retrovir
zidovudin
azt
figur
origin
look
cancer
although
compound
alon
prove
lifesav
mani
aid
patient
efficaci
ideal
toxic
form
neutropenia
sever
anemia
liver
disord
encount
patient
furthermor
fast
sloppi
replic
process
viru
use
soon
gave
rise
mutat
resist
effect
drug
rt
inhibitor
soon
reach
market
includ
nucleosid
later
nonnucleosid
nnrti
act
targetincrement
improv
still
far
ideal
major
advanc
aid
therapi
came
identif
anoth
target
hiv
proteas
mention
sampl
renin
inhibitor
compound
collect
pharma
compani
provid
lead
even
firstinclass
compound
roch
inviras
saquinavir
approv
sale
gener
knowledg
work
drug
real
futur
would
lie
combin
rt
inhibitor
proven
cours
addit
target
hiv
fusion
inhibitor
integras
inhibitor
etc
continu
pursu
new
firstinclass
drug
expect
find
market
combin
therapi
aid
improv
live
mani
patient
drug
act
new
target
still
find
market
space
therapeut
area
drug
alreadi
exist
imagin
effect
current
therapi
might
includ
new
diseas
like
sever
acut
respiratori
syndrom
sar
assum
compani
want
gambl
eventu
becom
lucr
market
old
one
exist
drug
treat
symptom
find
someth
would
major
accomplish
would
valu
counterbalanc
advantag
cours
sever
major
disadvantag
alreadi
seen
despit
new
improv
technolog
use
process
preclin
tv
often
slow
resourc
intens
wors
still
sometim
predict
clinic
result
last
factor
discourag
late
stage
efficaci
failur
expens
well
discourag
sort
project
failur
less
sever
still
real
limit
involv
pursu
novel
target
fact
assay
may
need
develop
reagent
thing
like
protein
interest
target
substrat
proteolyt
enzym
may
need
made
valid
even
begin
might
simpli
matter
brows
catalog
reagent
kit
track
procedur
method
enzymolog
real
work
might
need
go
mean
fte
need
approv
manag
specul
project
nt
even
begun
yet
like
small
molecul
act
prospect
target
wo
nt
known
either
seen
small
molecul
inhibitor
agonist
antagonist
fine
tool
biologist
dispos
tv
could
tool
molecul
would
nt
avail
project
full
swing
lead
optim
lo
mode
compani
unlik
enter
target
better
valid
sort
normal
would
mean
valid
would
need
progress
without
small
molecul
tool
one
way
base
prefer
target
famili
bind
structur
similar
compound
note
earlier
call
chemogenom
dr
mark
murcko
vertex
pharmaceut
provid
exampl
might
work
realworld
project
area
kinas
ion
channel
gpcr
alreadi
work
member
famili
note
alreadi
knowhow
set
assay
field
may
alreadi
use
compoundsnot
drug
candid
perhapsbut
pretti
decent
start
point
let
say
read
paper
natur
suggest
kinas
x
great
target
cancer
specul
choic
choic
noth
wait
year
till
public
valid
b
put
lot
biologist
project
tri
make
sens
c
collabor
somebodi
academia
expert
target
use
surrog
biologistwhich
sort
variat
bor
could
say
well
gee
three
month
get
assay
run
screen
kinas
deck
see
nm
inhibitor
kinas
x
take
primari
cell
cancer
type
see
whether
anyth
interest
done
actual
less
work
way
labori
biolog
upfront
lucki
find
molecul
pretti
good
given
tool
biologist
go
basic
biolog
studi
target
tool
would
nt
otherwis
pursu
target
tool
compound
use
rnai
biolog
tool
would
easier
faster
biologist
need
tool
compound
view
small
molecul
select
cell
permeabl
alway
better
tool
add
fact
success
nm
tool
compound
might
also
nm
lead
compound
chemistri
work
ip
issu
look
structureact
relationship
sar
may
alreadi
exist
analog
also
screen
got
quit
good
strategi
keep
mind
reli
screen
compound
direct
famili
target
alreadi
avail
second
cousin
someth
look
littl
like
someth
might
possibl
activ
would
need
start
make
compound
scratch
whole
differ
stori
great
potenti
market
drug
act
new
target
delay
due
need
valid
somewhat
amelior
front
load
sometim
even
workaround
problem
tool
compound
nt
everyon
work
novel
target
rememb
major
advantag
work
establish
target
fact
result
drug
higherthanaverag
probabl
make
market
probabl
predict
major
disadvantag
work
novel
target
simpli
use
readili
avail
onlin
resourc
like
biospac
wwwbiospacecom
drugresearchercom
wwwdrugresearchercom
without
delv
deeper
like
abl
locat
averag
least
one
report
excit
potenti
new
target
everi
day
today
exampl
usual
sourc
alert
heme
potenti
role
kaposi
sarcoma
yesterday
brought
report
role
lysyl
oxidas
lox
cancer
metastasi
promis
drug
act
metabotrop
glutam
receptor
mglur
fragil
x
syndrom
three
repres
laudabl
accomplish
hold
promis
victim
cancer
common
inherit
form
mental
impair
mani
eventu
result
market
drug
make
conserv
estim
novel
target
report
rate
one
per
day
guesstim
anoth
uncov
industri
talk
secreci
especi
import
earli
stage
project
give
us
new
target
everi
year
given
year
drug
act
novel
target
approv
seven
eight
approv
would
make
banner
year
gloss
factor
like
time
lag
tv
drug
approv
unpredict
chang
number
approv
drug
etc
see
least
new
target
lead
market
drug
recent
estim
state
although
project
base
establish
target
like
enter
preclin
develop
result
optim
lead
evalu
preclin
stage
project
base
new
target
ever
get
far
way
seen
take
credit
away
dedic
often
brilliant
research
hard
work
uncov
origin
instead
failur
launch
could
due
number
thing
anyon
ever
made
compound
describ
literatur
know
experi
sometim
end
difficult
research
reproduc
real
followup
might
done
compani
believ
market
small
difficult
nt
fit
research
portfolio
lost
shuffl
project
competit
corpor
merger
perhap
felt
publish
work
fell
nih
invent
categori
nt
intern
standard
perhap
varieti
reason
suitabl
compound
could
found
could
nt
thennew
renin
inhibitor
year
one
reason
anoth
propos
target
never
abl
work
way
rung
valid
ladder
might
mani
reason
bottom
line
novel
target
plenti
novel
approv
drug
act
upon
piti
cellular
assay
play
import
role
everi
project
project
base
upon
given
target
initi
vitro
assay
usual
follow
target
assay
take
place
cell
exampl
proteasom
inhibitor
project
would
probabl
begin
screen
compound
inhibit
isol
proteasom
would
follow
studi
activ
compound
incub
cell
level
marker
cellular
proteasom
function
like
protein
tend
accumul
proteasom
nt
activ
degrad
measur
compound
activ
first
assay
work
cell
everyon
feel
confid
onto
someth
usual
villain
cell
imperm
cellular
efflux
face
project
continu
think
kind
simpl
cellular
assay
rite
passag
targetdriven
project
cellular
assay
also
use
total
differ
way
understand
need
take
brief
look
genet
timetest
genet
techniqu
find
role
specif
protein
biochem
pathway
use
mutagenesi
live
organ
randomli
interfer
gene
product
focu
mutat
caus
observ
effect
phenotyp
go
back
identifi
genet
alter
result
perturb
protein
respons
process
goe
name
forward
genet
mutagenesi
usual
accomplish
random
mutat
induc
nasti
chemic
mutagen
like
enu
ethylnitrosourea
instead
use
perturbogen
librari
small
molecul
rather
caus
mutat
might
interact
cellular
protein
inhibit
antagon
agon
process
becom
known
forward
chemic
genet
figur
simpl
schemat
illustr
work
start
clean
slate
even
target
identifi
cellular
assay
devis
measur
observ
phenotyp
like
viabil
morpholog
chang
give
readout
like
protein
transloc
reflect
given
diseas
state
strike
one
prespecifi
target
direct
exampl
would
type
pathogen
bacteria
compound
induc
death
bacteriocid
failur
prolifer
bacteriostat
would
consid
potenti
use
assum
nt
human
cellsa
big
assumpt
case
would
nt
matter
least
initi
target
involv
everyth
could
thrown
assay
mechan
action
interest
hit
could
sort
later
gener
sort
strategi
use
mani
decad
antibiot
although
necessarili
highthroughput
basi
reminisc
way
interest
petri
dish
sir
alexand
fleme
gave
world
penicillin
inhibit
prolifer
cancer
cell
line
happen
number
differ
mechan
exampl
simpl
multitarget
cellular
assay
strategi
might
use
approach
stand
normal
process
complet
head
instead
go
target
drug
proce
drug
sens
hit
lead
target
way
repres
return
older
drug
discoveri
methodolog
prevail
day
broth
extract
screen
tissu
even
whole
anim
primari
assay
synthes
compound
back
new
field
molecular
biolog
shone
bright
spotlight
scientif
inquiri
specif
molecular
target
although
nobodi
suggest
turn
spotlight
mani
peopl
feel
illumin
rest
stage
well
could
help
context
phenotyp
screen
type
multitarget
highcont
screen
hc
usual
impli
use
subcellular
fluoresc
imag
repres
valuabl
addit
armamentarium
drug
discoveri
lot
divers
kind
assay
carri
enabl
recent
technolog
abil
detect
cell
morpholog
chang
microscopi
highthroughput
format
cell
cours
nt
constitut
vivo
system
except
case
singlecel
organ
also
engin
express
thing
like
known
chemotherapi
resist
factor
compound
screen
abil
restor
antiprolif
effect
cancer
drug
like
doxorubicin
case
tradit
cellular
model
hard
come
hcv
nt
amen
simpl
infect
reproduct
cultur
hepatocyt
cell
engin
express
selfamplifi
minigenom
call
replicon
contain
nonstructur
viral
protein
repres
conceiv
antivir
target
compound
activ
assay
might
hit
true
organ
rather
cell
nematod
c
elegan
zebrafish
embryo
danio
rerio
use
multitarget
assay
readout
simpl
fluoresc
complex
detail
analysi
modifi
protein
pathway
even
begin
understand
possibl
variat
type
screen
strategi
daunt
prospect
howev
mani
howev
complex
may
coupl
thing
common
allow
one
screen
drug
complex
live
system
real
world
isol
enzym
receptor
bind
assay
cast
much
wider
net
targetbytarget
approach
overal
summari
advantag
disadvantag
use
type
drug
discoveri
methodolog
shown
box
singl
biggest
advantag
method
definit
hit
give
real
effect
cell
rather
effect
isol
target
may
may
work
cellular
milieu
test
later
note
howev
initi
hit
defin
arbitrari
level
respons
highor
mediumthroughput
screen
valid
run
posit
control
requir
certain
amount
followup
conclus
drawn
simpl
look
raw
data
screen
artifact
must
rule
ident
puriti
good
doserespons
need
establish
discuss
chapter
followup
experi
done
hit
confirm
especi
addit
evid
like
confirm
differ
cell
line
appar
nonflat
sar
structur
relat
compound
screen
set
present
left
end
day
month
like
hit
produc
biolog
effect
diseaserelev
cellular
assay
valu
nt
underestim
confirmatori
experi
rule
insolubl
visual
examin
nephelometri
etc
toxic
cell
viabil
experi
bad
thing
genuin
hit
provid
unusu
good
start
point
compound
optim
furthermor
target
hit
turn
intracellular
mani
sure
compound
certain
degre
cell
permeabl
end
start
point
far
ahead
get
type
project
furthermor
approach
possibl
go
blind
without
prejudg
target
may
present
type
compound
hit
may
like
result
discoveri
new
target
novel
compound
find
anyth
case
inform
nt
known
sort
phenomenolog
approach
may
way
go
target
inform
avail
bia
still
built
desir
exampl
select
librari
fuse
nitrogen
heterocycl
look
like
kinas
inhibitor
cancer
cellular
assay
anoth
advantag
approach
may
obviou
first
compound
whose
effect
depend
hit
one
sever
differ
target
may
discard
targocentr
approach
precis
nonselect
combin
nt
consid
still
identifi
fact
cellular
screen
may
best
way
studi
thing
like
kinas
inhibitor
one
recent
studi
conclud
cellular
respons
induc
multiplex
protein
kinas
inhibitor
may
emerg
properti
understood
fulli
consid
sum
individu
inhibitorkinas
interact
number
multitarget
compound
popul
world
known
drug
see
later
particularli
appeal
therapeut
area
multitarget
compound
oncolog
mani
differ
gene
product
typic
mutat
phenotyp
assay
antiprolif
proapoptot
etc
straightforward
yet
anoth
uniqu
aspect
phenotyp
screen
might
even
detect
prodrug
activ
speci
compound
appli
transform
version
isoniazid
isonicotinyl
hydrazid
tuberculosi
drug
widespread
use
half
centuri
requir
reaction
specif
peroxidas
follow
reaction
nad
nadp
gener
nucleotid
adduct
activ
speci
recent
studi
use
chemic
genet
approach
identifi
one
target
specif
nucleotid
adduct
bacteri
dihydrofol
reductas
isoniazid
origin
came
simpl
bacteriocid
box
advantag
compound
emerg
cellular
valid
target
toxic
insolubl
unstabl
compound
filter
intracellular
target
hit
impli
cell
permeabl
lead
uncov
absenc
target
inform
novel
drug
act
multipl
target
identifi
identifi
unexpect
prodrug
disadvantag
involv
expens
equip
licens
lengthi
assay
develop
diseas
relev
high
throughput
cellular
model
extens
tid
work
probabl
involv
chemistri
requir
target
might
difficult
identifi
undesir
section
target
aris
phenotyp
highcont
screen
phenotyp
assay
discov
today
elucid
multipl
moa
sever
import
metabolit
would
repres
quit
challeng
drug
develop
importantli
though
would
virtual
imposs
discov
targetcent
approach
use
phenotyp
multitarget
highcont
approach
drug
discoveri
downsid
well
first
hightech
natur
mani
sophist
assay
techniqu
involv
mean
licens
need
taken
often
expens
licens
fee
paid
assay
even
done
exampl
includ
use
green
fluoresc
protein
gfp
frequent
employ
report
gene
previous
mention
hcv
replicon
assay
hcv
particularli
expens
area
research
sinc
fee
also
need
paid
chiron
novarti
owe
groundbreak
work
done
scientist
own
viral
genom
patent
expens
associ
project
includ
special
equip
well
cost
associ
frequent
lengthi
assay
develop
process
trickier
usual
enzym
receptor
screen
cell
somewhat
delic
caprici
fact
area
like
cn
indic
good
diseaserelev
cellular
assay
may
avail
owe
complex
natur
disord
may
adequ
model
singl
cultur
cell
type
even
therapeut
area
cellular
model
exist
like
cancer
guarante
transform
cell
line
typic
use
like
discuss
later
respond
drug
way
actual
tumor
compos
mani
primari
cell
type
live
die
varieti
differ
aerob
anaerob
environ
even
cancer
cell
line
exhibit
differ
behavior
presenc
cell
secret
factor
influenc
prolifer
death
come
surpris
drug
level
valid
assay
might
make
model
someth
expect
get
drive
away
biggest
drawback
use
approach
drug
discoveri
becom
obviou
hit
identifi
confirmedwhat
exactli
hit
wide
use
drug
includ
recent
year
aspirin
act
upon
unknown
target
drug
candid
still
enter
clinic
way
recent
exampl
intermun
pirfenidon
figur
investig
new
drug
idiopath
pulmonari
fibrosi
ipf
propos
moa
map
kinas
inhibit
first
suggest
phase
iii
test
drug
might
even
make
market
without
known
moa
realiti
drug
go
clinic
without
known
target
seriou
disadvantag
mani
compani
reluct
pursu
reason
everyon
involv
includ
fda
feel
comfort
moa
known
clinician
particular
need
feel
would
fit
exist
therapi
base
mechan
although
drug
unknown
moa
continu
approv
go
without
one
make
rougher
road
know
moa
earli
stage
would
far
prefer
might
allow
chemist
use
structur
base
drug
design
sbdd
rapid
optim
know
target
also
give
scientist
idea
antitarget
relat
protein
possibl
respons
toxic
might
real
world
identif
hit
use
phenotyp
screen
inevit
follow
attempt
determin
target
target
give
effect
target
identif
case
base
real
cellular
effect
instead
correl
evid
theori
avoid
postpon
come
excit
new
lead
found
phenotyp
screen
timelin
therefor
short
resourc
need
pour
far
trivial
effort
may
even
call
biologist
small
compani
avail
addit
chemist
probabl
need
earli
could
sever
reason
initi
hit
often
weak
say
mm
use
determin
target
certain
amount
blind
optim
need
done
front
structur
modif
involv
linker
andor
label
may
need
carri
fish
target
protein
discuss
much
excit
gener
chemist
becom
eager
start
make
analog
case
requir
commit
least
chemist
still
highli
specul
preproject
fte
need
plan
advanc
avoid
prematur
predict
project
termin
lack
resourc
later
said
done
three
possibl
outcom
tid
approach
target
phenotyp
lead
discov
found
fit
establish
target
bin
often
case
compani
need
decid
whether
pursu
exampl
uncov
antibacteri
agent
act
inhibit
dna
gyras
target
fluoroquinolon
like
cipro
ciprofloxacin
figur
would
put
compani
section
target
aris
phenotyp
highcont
screen
posit
go
pro
con
mention
section
busi
decis
would
call
might
might
favor
one
though
least
start
cell
permeabl
hope
novel
lead
could
jumpstart
project
lo
stage
second
possibl
novel
target
uncov
advantag
work
novel
target
appli
one
disadvantag
requir
valid
least
mitig
start
compound
work
cell
although
higher
risk
failur
due
lack
valid
remain
project
least
excit
everyon
involv
third
possibl
shown
figur
timelin
origin
set
target
determin
run
target
still
identifi
disturb
three
outcom
real
possibl
owe
often
ratelimit
natur
process
modern
techniqu
see
resourc
term
peopl
expertis
fund
brought
bear
possibl
identifi
target
target
cellular
lead
assum
unlimit
resourc
includ
time
situat
never
exist
real
world
determin
target
compound
found
phenotyp
screen
never
trivial
real
possibl
budget
time
requir
could
end
insupport
decis
whether
continu
investig
increas
resourc
push
timelin
need
made
second
decis
whether
go
seriou
lo
blind
without
critic
target
inform
also
need
follow
point
drug
made
clinic
even
approv
way
whatev
outcom
see
tid
play
critic
role
phenotypebas
project
subject
recent
review
time
look
common
techniqu
use
import
step
shown
box
mani
case
idea
potenti
target
might
exist
compound
even
screen
alway
usual
suspect
base
known
pathwaystubulin
binder
antiprolif
assay
gene
product
cancer
drug
resist
etc
educ
guess
followup
often
prove
success
case
eleg
exampl
kind
knowledgebas
approach
report
kau
et
al
librari
highcont
screen
inhibitor
transcript
factor
nuclear
export
turn
number
small
molecul
hit
michael
acceptor
known
compound
leptomycin
b
figur
also
michael
acceptor
act
upon
nuclear
export
receptor
form
coval
adduct
protein
sulfhydryl
group
hypothesi
new
hit
also
act
target
via
mechan
subsequ
born
followup
experi
direct
method
identifi
molecular
target
phenotyp
screen
hit
involv
affin
purif
strong
bind
interact
target
drug
least
theori
mean
drug
attach
solid
support
part
molecul
unimport
interact
target
extract
lysat
contain
target
pass
target
bind
suffici
well
mani
cellular
protein
soup
wash
away
stronger
condit
elut
buffer
highion
strength
cleavag
linker
drugprotein
complex
solid
support
allow
isol
drugtarget
complex
character
analyz
usual
lcmsm
reveal
ident
target
protein
poster
child
sort
approach
groundbreak
work
dr
stuart
schreiber
group
determin
biolog
target
import
immun
suppress
figur
protein
call
fkbp
work
elucid
moa
drug
call
tacrolimu
allow
organ
transplant
patient
avoid
transplant
reject
live
mani
year
also
accord
dr
thoma
kodadek
professor
medicin
univers
texa
southwest
medic
center
lot
convinc
biologist
realli
might
someth
idea
use
chemistri
key
tool
molecular
biolog
also
suggest
recalcitr
synthet
chemistri
commun
might
ok
work
real
biolog
system
bad
news
continu
creat
fals
impress
among
chemist
without
much
classic
biochem
experi
target
identif
problem
could
solv
case
use
simpl
affin
chromatographi
approach
view
soon
crash
upon
rock
realiti
case
complex
receptor
rel
abund
cell
ligand
possess
high
singl
digit
nanomolar
affin
two
thing
true
mani
case
phenotyp
screen
commonli
turn
lead
doubl
perhap
singl
digit
micromolar
rang
problem
use
affin
purif
becom
one
signaltonois
wash
away
sticki
nontarget
protein
without
also
wash
away
relev
low
affin
target
addit
chemic
modifi
origin
hit
link
solid
support
nt
necessarili
trivial
especi
absenc
knowledg
import
target
bind
kind
preliminari
sar
studi
may
need
done
linker
attach
variou
posit
hit
molecul
order
find
accept
spot
one
interest
approach
build
linker
origin
screen
librari
exemplifi
recent
work
target
triazin
hit
zebrafish
embryo
morpholog
screen
identifi
compon
ribosom
anoth
nice
exampl
use
affin
purif
phenotyp
tid
report
tanaka
et
al
morpholog
phenotyp
screen
reveal
hydroxylcontain
analog
kinas
inhibitor
pp
gave
rise
uniqu
cellular
effect
affin
purif
trace
nonkinas
target
thu
affin
purif
proven
success
time
time
like
everi
mean
tid
mean
univers
surpris
mani
differ
methodolog
develop
quit
involv
use
techniqu
molecular
biolog
express
larg
number
protein
expos
tag
tether
small
molecul
hit
detect
interact
determin
target
involv
among
phage
display
three
hybrid
system
latter
normal
use
yeast
also
use
mammalian
system
involv
link
hit
known
ligand
protein
receptor
use
bifunct
molecul
bait
bring
togeth
domain
requir
activ
report
gene
presenc
hit
target
anoth
techniqu
involv
microarray
cell
engin
differ
plasmid
overexpress
variou
protein
use
appropri
label
hit
allow
tid
although
far
literatur
exampl
involv
limit
subset
potenti
protein
target
genomewid
array
rel
direct
method
make
use
array
protein
bound
glass
slide
also
use
likewis
limit
note
year
immobil
array
protein
difficult
make
less
stabl
dna
microarray
case
one
potenti
advantag
identif
method
mention
detect
techniqu
call
surfac
plasmon
reson
spr
obviat
need
hit
modif
via
label
linker
use
theori
one
direct
way
find
target
hit
act
unknown
mechan
simpli
look
effect
cellular
protein
observ
differ
protein
express
composit
presenc
absenc
hit
molecul
use
gel
practic
anyth
simpl
owe
mani
factor
sheer
number
protein
involv
normal
differ
abund
perhap
million
fold
activ
isol
difficulti
experiment
variabl
massiv
data
handl
mani
protein
like
differenti
express
analyz
data
often
result
haystack
needl
real
target
could
indistinguish
crowd
differenti
express
protein
hide
plain
sight
said
techniqu
success
one
instanc
comparison
gel
antiprolif
natur
product
show
small
shift
protein
trace
incorpor
singl
ntermin
methionin
residu
treat
cell
suggest
compound
act
inhibitor
methionin
aminopeptidas
metap
major
simplif
kind
proteom
techniqu
involv
limit
number
protein
studi
smaller
subset
gene
product
cystein
proteas
metalloproteas
appropri
activ
base
probe
abp
exist
virtu
target
bind
mechan
depend
activ
abund
anoth
obfusc
factor
eschew
well
relev
kind
strategi
probabl
limit
case
gene
famili
interest
target
direct
librari
first
place
even
could
nt
rule
effect
nonfamili
target
per
se
within
tight
constraint
power
method
identifi
target
variat
whole
genom
proteom
involv
transcript
profil
comparison
hit
pattern
gene
express
signatur
perturbogen
known
drug
use
dna
chip
figur
illustr
concept
collect
known
transcript
profil
requir
comparison
might
obtain
public
databas
librari
sever
hundr
sever
thousand
known
drug
compil
test
purpos
exampl
involv
research
analyz
effect
compound
protein
express
cell
line
determin
dna
microarray
gene
analysi
truli
mindboggl
amount
data
reveal
cluster
drug
act
similar
mechan
tubulin
stabil
dhfr
inhibitor
etc
profil
hit
anticanc
phenotyp
screen
gene
chip
compar
known
pattern
might
place
appropri
moa
bin
anoth
approach
would
use
transcriptom
proteom
per
se
direct
comparison
growth
inhibitori
valu
cell
line
known
drug
use
onlin
program
compar
name
impli
drug
act
mechan
tend
display
similar
profil
show
part
profil
one
anticanc
drug
vincristin
red
bar
left
indic
less
averag
activ
cell
line
go
right
indic
greater
averag
potenc
correspond
cell
regardless
readout
use
signaturebas
approach
provid
valuabl
mechanist
insight
limit
util
identifi
novel
target
may
equal
novel
signatur
still
uniqu
profil
data
point
well
worth
transcript
profil
unknown
custombuilt
signatur
databas
illustr
studi
profil
small
set
antibacteri
compound
obtain
use
classifi
relev
moa
other
anoth
librari
small
molecul
develop
use
elucid
moa
antiprolif
agent
comparison
databas
limit
small
molecul
perturbogen
also
make
use
profil
gener
genet
method
delet
mutant
yeast
excel
recent
review
subject
point
fact
iron
twist
fate
true
genet
method
like
genedelet
mutant
yeast
often
help
elucid
target
hit
obtain
chemic
genet
phenotyp
express
profil
case
observ
variabl
collect
almost
everi
gene
product
yeast
knock
gener
mutat
mimic
phenotyp
induc
hit
might
implic
moa
call
loss
function
lof
screen
altern
code
librari
heterozyg
yeast
mutant
treat
hit
look
mutat
caus
sensit
effectsin
effect
doserespons
experi
half
dose
induc
delet
known
gene
half
small
molecul
process
call
haploinsuffici
profil
done
cincreasin
figur
simpl
small
molecul
identifi
phenotyp
screen
one
delet
confer
greatest
sensit
protein
product
spindlecheckpoint
function
followon
experi
demonstr
fact
target
hit
opposit
kind
modif
make
cell
less
sensit
drug
might
indic
compensatori
multidrug
resist
mechan
also
use
yeast
cours
man
lot
easier
manipul
pathway
involv
similar
figur
cancer
drug
vincristin
inhibitor
cincreasin
section
target
aris
phenotyp
highcont
screen
chapter
present
brief
overview
new
drug
discoveri
project
begin
scienc
busi
decis
go
type
project
research
expect
see
littl
target
identifi
valid
although
knowledg
nt
exactli
state
secret
tri
gather
sever
disciplin
myriad
scatter
inform
sourc
mean
often
difficult
new
industri
get
big
pictur
overview
obvious
ca
nt
justic
depth
subtleti
knowledg
involv
field
mention
complex
drug
discoveri
process
even
profound
depth
understand
topic
could
result
much
effort
mani
year
research
would
still
understand
part
drug
discoveri
process
exampl
exactli
screen
compound
come
technolog
use
screen
hit
